RxMP Therapeutics
RxMP Therapeutics is dedicated to developing innovative therapies aimed at preventing and treating hemorrhage and excessive bleeding associated with trauma, surgery, or bleeding disorders. The company focuses on creating novel hemostatic agents that can effectively stop bleeding while minimizing the risk of unwanted clotting elsewhere in the body. Their lead product, RMP-402, has significant market potential and is backed by substantial funding to support its development.
RxMP Therapeutics is currently seeking investment
RxMP Therapeutics is seeking a investment in the range of
What We Do
Novel hemostatic agents based on red cell-derived microparticles (RMPs) that are manufactured from packed red blood cells through a scalable process. These agents are freeze-dried for long-term stability and can be administered systemically to prevent or treat excessive bleeding. RMPs do not trigger clotting themselves but enhance the normal clotting process, addressing various bleeding defects and potentially reversing effects of irreversible coagulation therapies.
Battlefield Resuscitation
Biologics
Routes of Administration
Key People
President and CEO, Director
CSO, Director
Director
Shawna Khouri, MBID
COO
News & Updates
Dr. Rif Pamukcu CEO and Dr. Mike Davis provide shareholders an update on the current raise and outlook for 2024.